Role of integrin-linked kinase in osteosarcoma progression

Journal of Orthopaedic Research

Volumn 31, Issue 10, 2013, Pages 1668-1675

  Rhee, Seung Hwan ^a   Han, Ilkyu ^b   Lee, Mi Ra ^c   Cho, Hwan Seong ^d   Oh, Joo Han ^d   Kim, Han Soo ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University Cancer Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

angiogenesis; apoptosis; integrin linked kinase; invasion; osteosarcoma

Indexed keywords

INTEGRIN LINKED KINASE; LIPOCORTIN 5; SMALL INTERFERING RNA; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; DISTANT METASTASIS; ELISA KIT; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE;

ANGIOGENESIS; APOPTOSIS; INTEGRIN-LINKED KINASE; INVASION; OSTEOSARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BONE NEOPLASMS; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84882887862     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22409     Document Type: Article

References (50)

1. Ham SJ, Schraffordt Koops H, van der Graaf WT, et al. 1998. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol 24: 584-600.
2. Longhi A, Errani C, De Paolis M, et al. 2006. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436.
3. Papagelopoulos PJ, Galanis EC, Vlastou C, et al. 2000. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 23: 858-867; quiz 868-859.
4. Bacci G, Lari S., 2001. Current treatment of high grade osteosarcoma of the extremity: review. J Chemother 13: 235-243.
5. Foster L, Dall GF, Reid R, et al. 2007. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br 89: 1234-1238.
6. Grimer RJ., 2005. Surgical options for children with osteosarcoma. Lancet Oncol 6: 85-92.
7. Wilkins RM, Cullen JW, Camozzi AB, et al. 2005. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res 438: 128-136.
8. Messerschmitt PJ, Rettew AN, Brookover RE, et al. 2008. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 466: 2168-2175.
9. Clark JC, Dass CR, Choong PF., 2008. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297.
10. Grimer RJ, Taminiau AM, Cannon SR., 2002. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 84: 395-400.
11. Quan GM, Choong PF., 2006. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 25: 707-713.
12. Briccoli A, Rocca M, Salone M, et al. 2010. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy 1985-2005. Surgical oncology 19: 193-199.
13. Grimer RJ, Sommerville S, Warnock D, et al. 2005. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 41: 578-583.
14. Kempf-Bielack B, Bielack SS, Jurgens H, et al. 2005. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568.
15. Bielack SS, Kempf-Bielack B, Branscheid D, et al. 2009. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27: 557-565.
16. Akiyama T, Dass CR, Choong PF., 2008. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7: 3461-3469.
17. Chou AJ, Geller DS, Gorlick R., 2008. Therapy for osteosarcoma: where do we go from here ? Paediatr Drugs 10: 315-327.
18. Mintz MB, Sowers R, Brown KM, et al. 2005. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754.
19. Guise TA, Yin JJ, Mohammad KS., 2003. Role of endothelin-1 in osteoblastic bone metastases. Cancer 97: 779-784.
20. Wuyts W, Van Wesenbeeck L, Morales-Piga A, et al. 2001. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 28: 104-107.
21. Bjornsti MA, Houghton PJ., 2004. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
22. Casas-Ganem J, Healey JH., 2005. Advances that are changing the diagnosis and treatment of malignant bone tumors. Curr Opin Rheumatol 17: 79-85.
23. McGary EC, Weber K, Mills L, et al. 2002. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591.
24. Ahmed N, Riley C, Oliva K, et al. 2003. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 201: 229-237.
25. Dai DL, Makretsov N, Campos EI, et al. 2003. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9: 4409-4414.
26. Ito R, Oue N, Zhu X, et al. 2003. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch 442: 118-123.
27. Kaneko Y, Kitazato K, Basaki Y., 2004. Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor. J Cell Sci 117: 407-415.
28. Persad S, Dedhar S., 2003. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 22: 375-384.
29. Somasiri A, Howarth A, Goswami D, et al. 2001. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 114: 1125-1136.
30. Tan C, Cruet-Hennequart S, Troussard A, et al. 2004. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5: 79-90.
31. Troussard AA, Costello P, Yoganathan TN, et al. 2000. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 19: 5444-5452.
32. Bravou V, Klironomos G, Papadaki E, et al. 2006. ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol 208: 91-99.
33. Marotta A, Parhar K, Owen D, et al. 2003. Characterisation of integrin-linked kinase signalling in sporadic human colon cancer. Br J Cancer 88: 1755-1762.
34. Takanami I., 2005. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 5: 1.
35. Sawai H, Okada Y, Funahashi H, et al. 2006. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 25: 3237-3246.
36. Graff JR, Deddens JA, Konicek BW, et al. 2001. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 7: 1987-1991.
37. Engelman MD, Grande RM, Naves MA, et al. 2012. Integrin-linked kinase (ILK) expression correlates with tumor severity in clear cell renal carcinoma. Pathol Oncol Res 19: 27-33.
38. Rosen G, Caparros B, Huvos AG, et al. 1982. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230.
39. Koo CL, Kok LF, Lee MY, et al. 2009. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 7: 25.
40. Kaya M, Wada T, Akatsuka T, et al. 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577.
41. Diaz-Montero CM, McIntyre BW., 2003. Acquisition of anoikis resistance in human osteosarcoma cells. Eur J Cancer 39: 2395-2402.
42. Hinton CV, Avraham S, Avraham HK., 2008. Contributions of integrin-linked kinase to breast cancer metastasis and tumourigenesis. J Cell Mol Med 12: 1517-1526.
43. Attwell S, Roskelley C, Dedhar S., 2000. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 19: 3811-3815.
44. Chung DH, Lee JI, Kook MC, et al. 1998. ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch 433: 113-117.
45. Papachristou DJ, Gkretsi V, Rao UN, et al. 2008. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: association with prognostic significance. Eur J Cancer 44: 2518-2525.
46. Younes MN, Kim S, Yigitbasi OG, et al. 2005. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4: 1146-1156.
47. Younes MN, Yigitbasi OG, Yazici YD, et al. 2007. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 133: 15-23.
48. Han S, Sun X, Ritzenthaler JD, et al. 2009. Fish oil inhibits human lung carcinoma cell growth by suppressing integrin-linked kinase. Mol Cancer Res 7: 108-117.
49. Liu J, Costello PC, Pham NA, et al. 2006. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 1: 771-779.
50. Hannigan G, Troussard AA, Dedhar S., 2005. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5: 51-63.